Brief: Epigenomics Reduction Of Principal Amount Of Planned Mandatory Convertible Bond
20/08/2021 09:43
Aug 20 (Reuters) - EPIGENOMICS AG ECXn.DE :
* REDUCTION OF PRINCIPAL AMOUNT OF PLANNED MANDATORY
CONVERTIBLE
BOND TO UP TO EUR 16.5 MILLION AND OF CONVERSION PRICE TO EUR
1.10 PER SHARE
* TO REDUCE CONVERSION PRICE TO EUR 1.10
* AGGREGATE PRINCIPAL AMOUNT OF MANDATORY CONVERTIBLE BOND
ALSO
DECREASES TO EUR 16,500,000.00, CONSISTING OF 165,000 NOTES WITH
A NOMINAL AMOUNT OF EUR 100.00 EACH
* OTHERWISE, TERMS OF MANDATORY CONVERTIBLE BOND AS
ANNOUNCED ON
JUNE 11, 2021 REMAIN UNCHANGED.
* TERMS OF MANDATORY CONVERTIBLE BOND AS ANNOUNCED ON JUNE
11,
2021 REMAIN UNCHANGED
* OBLIGATION WILL LAPSE UPON END OF 2023
Source text for Eikon: ID:nEQ3HKTlYa
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns